Cancer Gene Therapy Market Size, Share Global Analysis Report, 2020–2026

Industry Insights

The Cancer gene therapy market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Cancer gene therapy market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

This specialized and expertise-oriented industry research report scrutinizes the technical and commercial business outlook of the Cancer gene therapy industry. The report analyzes and declares the historical and current trends analysis of the Cancer gene therapy industry and subsequently recommends the projected trends anticipated to be observed in the Cancer gene therapy market during the upcoming years.

Key Insights from Primary Research

• As per our primary respondents, the Cancer gene therapy market is set to grow annually at a rate of around 23%.
• It was established through primary research that the Cancer gene therapy market was valued at around USD 800 million in 2019.
• After secondary research, we performed face-to-face interviews to validate our data. The insights interviewees declared that Ex-vivo is the most used type for the global cancer gene therapy market.
• On the basis of the product, the Non-viral Vectors segment dominated the global cancer gene therapy market in 2019. It accounted for around 47% share of the total market in 2019.
• The Biopharma companies segment, on the basis of end-use segmentation, was the leading revenue-generating category accounting for around 59% share, in 2019.

Key Recommendations from Analysts

• Based on the exhaustive secondary research done by our team, the Ex-vivo type is anticipated to become the most demanding type in the upcoming years, owing to the growing demand for Cancer gene therapy from the medical industry.
• As per our analysts, North America recorded the highest market share of more than 39% by 2026, and the market is expected to bolster in this region, resulting in creating lucrative opportunities for new players.
• Growing at a CAGR of around 23%, the Cancer gene therapy market provides numerous opportunities for all of the involved stakeholders across the entire value chain.
• Our analysts have identified Ex-vivo and Non-viral Vectors categories as the leading investment pockets for the Cancer gene therapy market in terms of type and application segmentation respectively.
• Our analysts recommend that emerging players focus on Research institutes owing to the substantial growth of the pharmaceutical and medical industry worldwide.

Market Attractiveness – By Type

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer gene therapy industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the Cancer gene therapy industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the Cancer gene therapy market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the Cancer gene therapy industry. The Cancer gene therapy market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the Cancer gene therapy sector. Key strategic developments in the Cancer gene therapy market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Cancer gene therapy market are appropriately highlighted in the report.

The cancer gene therapy market accounted for approximately USD 800 million in 2019. The market is projected to grow at a CAGR of 23% and is anticipated to reach around USD 3,400 million by 2026.

A growing number of cancer patients and an increasing geriatric population base are important factors contributing to the growth of the world market in cancer gene therapy. Every year there is an increase in cancer patients worldwide. Cancer is the second leading cause of death in 2016, according to the WHO. It is also believed that one in six deaths was caused by cancer. Another important factor in the prevalence of cancer gene therapy is the increase in R&D activities, owing to significant investments in cancer gene therapy.

The Cancer gene therapy market research report delivers an acute valuation and taxonomy of the Cancer gene therapy industry by practically splitting the market on the basis of different types, applications, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the Cancer gene therapy industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. Further, country-wise data for the Cancer gene therapy industry is provided for the leading economies of the world.

The Cancer gene therapy market is segmented based on Type, product, and end-user. On the basis of type segmentation, the market is classified into Ex-vivo and In-vivo. In terms of product segmentation, the market is bifurcated into Viral Vectors, Non-viral Vectors, and Others. By End-User, the market is divided into Biopharma companies, Research institutes, and Others.

Report Scope

Some of the essential players operating in the Cancer gene therapy market, but not restricted include

•  Vigene Biosciences
•  Sirion Biotech
•  Bluebird bio
•  Cellectis
•  Ziopharm
•  Cobra
•  Uniqure
•  Finvector
•  Sarepta Therapeutics

The taxonomy of the Cancer gene therapy industry by its scope and segmentation is as follows:

Global Cancer gene therapy Market: By Type Segmentation Analysis (Customizable)

• Ex-vivo
• In-vivo

Global Cancer gene therapy Market: By Product Segmentation Analysis (Customizable)

• Viral Vectors
• Non-viral Vectors
• Others

Global Cancer gene therapy Market: By End-Use Segmentation Analysis (Customizable)

• Biopharma companies
• Research institutes
• Others

Global Cancer gene therapy Market: Regional Segmentation Analysis (Customizable)

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of the Middle East & Africa